Population impact of HCV screening aged 40–64 years, total lifetime costs, health benefits, and incremental costs effectiveness ratio of combined screening and treatment strategies.

*Population weighted average (white male 44%, white female 45%, black male 5%, black female 6%) for fibrosis distribution: F0 13%, F1 51%, F2 13%, F3 10%, and F4 13%. All incremental cost and QALY are compared to the reference. Eligible screening population in the 40–64 year-old cohort is assumed at 83.5 million.ICER = incremental cost-effectiveness ratio; IL-28B = interleukin-28B; QALY = quality-adjusted life-year.“Dominated” indicates that the strategy costs more and provides fewer benefits than another strategy or a combination of two strategies.